|
Bioprocessing Trends: Annual Survey
|
|
|
| By
Michelle Hoffman
|
|
|
|
Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.
|
|
|
|
Industrializing Design, Development, and Manufacturing of Therapeutic Proteins
|
|
|
| By
Trevor J. Hallam
,
Christopher J. Murray
|
|
|
|
The authors discuss various approaches and related issues, including production of difficult-to express proteins using cell-free expression systems, scalability of protein expression, and site-specific chemical modifications.
|
|
|
|
Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy
|
|
|
| By
Tamara T. Monesmith
|
|
|
|
The authors developed automated equipment that uses functionally closed disposables to perform cellular and ribonucleic processing.
|
|
|
|
Peptide PEGylation: The Next Generation
|
|
|
| By
Baosheng Liu
|
|
|
|
Linking peptides to polyethylene glycol, or PEGylation, has helped improve pharmaceutical therapeutics in several ways. A wave of new techniques is now ushering in further advances.
|
|
|
|
Perspectives in MicroRNA Therapeutics
|
|
|
| By
Kevin Steffy
,
Charles Allerson
,
Balkrishen Bhat
|
|
|
|
The authors provide further insight into microRNA biology, and the simplicity of anti-miR oligonucleotide drug delivery.
|
|
|
|
Technologies for Downstream Processing in Biologics
|
|
|
| By
Margrit Holzer
|
|
|
|
The author describes recent developments to help overcome the downstream processing bottleneck. This article is part of a special issue on Sterile Manufacturing and Bioprocessing.
|
|
|
|
The Future of Downstream Processing
|
|
|
| By
Uwe Gottschalk
|
|
|
|
The author reviews the state of downstream processing and considers potential solutions, including the streamlining of full processes and borrowed technologies.
|
|
|
|
Strategies in Parenteral Drug Manufacturing
|
|
|
|
A technical forum moderated by Patricia Van Arnum
|
|
|
|
Regulation of Aseptic Processing in the 21st Century
|
|
|
| By
James E. Akers
,
James P. Agalloco
|
|
|
|
The authors question certain aspects of the industry's current regulatory-compliance strategy and suggest that aseptic-process control and evaluation should be revised.
|
|
|
